KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,515,305 | +64.2% | 317,519 | +33.1% | 0.01% | +100.0% |
| Q2 2023 | $3,359,488 | +30.2% | 238,600 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $2,580,119 | -27.5% | 239,788 | +1.0% | 0.00% | -25.0% |
| Q4 2022 | $3,556,926 | +147.0% | 237,445 | +111.7% | 0.00% | +100.0% |
| Q3 2022 | $1,440,000 | +246.2% | 112,171 | +161.3% | 0.00% | – |
| Q2 2022 | $416,000 | +186.9% | 42,928 | +248.5% | 0.00% | – |
| Q4 2021 | $145,000 | -83.6% | 12,317 | -75.4% | 0.00% | -100.0% |
| Q4 2020 | $885,000 | -43.6% | 50,089 | -51.1% | 0.00% | -50.0% |
| Q3 2020 | $1,569,000 | +24.7% | 102,386 | +107.3% | 0.00% | +100.0% |
| Q2 2020 | $1,258,000 | +255.4% | 49,382 | +89.0% | 0.00% | – |
| Q2 2019 | $354,000 | -79.4% | 26,134 | -72.6% | 0.00% | -100.0% |
| Q1 2019 | $1,720,000 | +541.8% | 95,256 | +898.3% | 0.00% | – |
| Q4 2018 | $268,000 | – | 9,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 2,374,392 | $36,376,000 | 4.43% |
| Opaleye Management Inc. | 338,000 | $8,778,000 | 1.72% |
| Lion Point Capital, LP | 495,748 | $7,594,000 | 1.67% |
| Fairmount Funds Management LLC | 212,746 | $3,259,000 | 1.38% |
| Vivo Capital, LLC | 1,151,622 | $17,643,000 | 1.02% |
| Spearhead Capital Advisors, LLC | 270,117 | $4,138,000 | 0.79% |
| Integral Health Asset Management, LLC | 120,000 | $1,838,000 | 0.56% |
| Endurant Capital Management LP | 117,480 | $1,800,000 | 0.53% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,990 | $3,983,000 | 0.39% |
| Ikarian Capital, LLC | 342,998 | $5,254,000 | 0.38% |